AnaptysBio Future Growth

Future criteria checks 1/6

AnaptysBio's earnings are forecast to decline at 16.6% per annum while its annual revenue is expected to grow at 19% per year. EPS is expected to decline by 1.9% per annum.

Key information

-16.6%

Earnings growth rate

-1.9%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	19.0%
Future return on equity	n/a
Analyst coverage	Good
Last updated	04 Sep 2024

Recent future growth updates

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Recent updates

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Jul 08

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Earnings and Revenue Growth Forecasts

NasdaqGS:ANAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36	-264	-285	-240	9
12/31/2025	32	-226	-162	-201	12
12/31/2024	32	-189	-17	-113	12
6/30/2024	30	-170	-130	-129	N/A
3/31/2024	23	-163	-134	-133	N/A
12/31/2023	17	-164	-122	-121	N/A
9/30/2023	15	-148	-98	-97	N/A
6/30/2023	13	-144	-79	-78	N/A
3/31/2023	11	-137	-78	-77	N/A
12/31/2022	10	-129	-74	-74	N/A
9/30/2022	4	-135	-88	-88	N/A
6/30/2022	24	-108	-78	-77	N/A
3/31/2022	53	-76	-45	-44	N/A
12/31/2021	63	-58	-47	-46	N/A
9/30/2021	122	8	15	17	N/A
6/30/2021	101	-9	5	7	N/A
3/31/2021	71	-30	-23	-22	N/A
12/31/2020	75	-20	-15	-14	N/A
9/30/2020	18	-74	-68	-68	N/A
6/30/2020	18	-81	-73	-73	N/A
3/31/2020	23	-84	-69	-69	N/A
12/31/2019	8	-97	-70	-70	N/A
9/30/2019	5	-94	-67	-66	N/A
6/30/2019	10	-79	-60	-59	N/A
3/31/2019	5	-69	-53	-52	N/A
12/31/2018	5	-62	-50	-49	N/A
9/30/2018	8	-52	-42	-41	N/A
6/30/2018	3	-45	-31	-30	N/A
3/31/2018	10	-34	N/A	-24	N/A
12/31/2017	10	-30	N/A	-19	N/A
9/30/2017	10	-27	N/A	-20	N/A
6/30/2017	13	-19	N/A	-19	N/A
3/31/2017	12	-15	N/A	-15	N/A
12/31/2016	17	-4	N/A	-9	N/A
9/30/2016	18	-4	N/A	-6	N/A
6/30/2016	19	-4	N/A	-5	N/A
3/31/2016	18	-6	N/A	-9	N/A
12/31/2015	18	-5	N/A	-10	N/A
9/30/2015	17	-2	N/A	-6	N/A
6/30/2015	19	0	N/A	-4	N/A
3/31/2015	18	1	N/A	-3	N/A
12/31/2014	16	0	N/A	15	N/A
12/31/2013	5	-6	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANAB's revenue (19% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ANAB's revenue (19% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANAB's Return on Equity is forecast to be high in 3 years time

AnaptysBio Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 20%

Price target increased by 10% to US$48.22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 48%

No longer forecast to breakeven

Recent updates

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

High number of new directors